23andMe Investor Presentation Deck

SPEED: Our lead IO program progressed from discovery to the clinic in 5 years 23andMe "IO Signature" Type 1 diabetes thyroid diseases celiac RA psoriasis SCC BCC Melanoma Variant 1 Variant 2 CTLA4 gene increased risk signed log (p) 10 5 -10 decreased risk 23ME-00610 Lead Asset (currently in Ph2a of Phase 1/2a trial) Cance Immune CD200 Ligand ● DOK2 CD200R1 Protein Receptor Immune Cancer Immune || Cancer Hashimoto' S Hypothyroidism BCC Program initiated: 2016 • Lead molecule generated by 23andMe • First human dosed: 2021 Investigator-assessed irAEs Genomic data successfully predicted '610 AE Profile 1400 mg 600 mg 200 mg- 60 mg 20 mg 6 mg 2 mg Q 5 10 15 20 % of Phase 1 Participants Hypothyrodism Pruritus Rash/Rash maculo-papular Copyright © 2024 23andMe, Inc. 25 23andMe 30 18

View entire presentation